A Mechanistic Model of the Intravitreal Pharmacokinetics of Large Molecules and the Pharmacodynamic Suppression of Ocular Vascular Endothelial Growth Factor Levels by Ranibizumab in Patients with Neovascular Age-Related Macular Degeneration

血管抑制剂 黄斑变性 血管内皮生长因子 药代动力学 药效学 化学 单克隆抗体 药理学 医学 脉络膜新生血管 眼科 抗体 生物物理学 癌症研究 血管内皮生长因子受体 免疫学 内科学 贝伐单抗 生物 化疗
作者
Laurence A. Hutton-Smith,Eamonn A. Gaffney,Helen M. Byrne,Philip K. Maini,Dietmar Schwab,Norman A. Mazer
出处
期刊:Molecular Pharmaceutics [American Chemical Society]
卷期号:13 (9): 2941-2950 被引量:63
标识
DOI:10.1021/acs.molpharmaceut.5b00849
摘要

Intravitreal injection of anti-VEGF (vascular endothelial growth factor) antibodies or antibody fragments has been shown to be a highly effective treatment for neovascular age-related macular degeneration (wet AMD). The ocular half-life (t1/2) of these large molecules, determined in ocular fluids or derived from serum levels, varies with molecular size and is larger in humans than in preclinical animal species. The high affinity binding of VEGF to these molecules lowers the free concentration of VEGF and reduces its occupancy on VEGF receptors in ocular tissues. To understand the biophysical determinants of t1/2 for anti-VEGF antibodies and the time-course of VEGF in ocular fluids, we developed a mechanistic model of intravitreal pharmacokinetics (IVT PK) for anti-VEGF antibodies and combined it with a mechanistic model of the pharmacodynamics (RVR PD) of VEGF suppression by ranibizumab, an anti-VEGF recombinant, humanized monoclonal antibody fragment (Fab). Our IVT PK model predicts that the ocular t1/2 of a large molecule will be approximately four-times the calculated value of its vitreous diffusion time (Tdiff), defined as rvit2/6D, where rvit is the radius of the vitreous chamber in that species (modeled as a sphere), and D is the diffusion coefficient of the molecule in physiological saline at 37 °C obtained from the Stokes–Einstein relation. This prediction is verified from a compilation of data and calculations on various large molecules in the human, monkey, rabbit, and rat and is consistent with the reported t1/2 values of ranibizumab in humans (mean value 7.9 days) and the calculated Tdiff of 1.59 days. Our RVR PD model is based on the publication of Saunders et al. (Br. J. Ophthalmol. 2015, 99, 1554−1559) who reported data on the time-course of VEGF levels in aqueous humor samples obtained from 31 patients receiving ranibizumab treatment for wet AMD and developed a compartmental mathematical model to describe the VEGF suppression profiles. We modified Saunders’ model with the known 2:1 stoichiometry of ranibizumab-VEGF binding and included the association and dissociation kinetics of the binding reactions. Using the RVR PD model, we reanalyzed Saunders’ data to estimate the in vivo dissociation constant (KD) between ranibizumab and VEGF. Our analysis demonstrates the delicate interrelationship between the in vivo KD value and the intravitreal half-life and yields an in vivo KD estimate that is appreciably larger than the in vitro KD estimates reported in the literature. Potential explanations for the difference between the in vivo and in vitro KD values, which appear to reflect the different methodologies and experimental conditions, are discussed. We conclude that the combined mechanistic model of IVT PK and RVR PD provides a useful framework for simulating the effects of dose, KD, and the molecular weight of VEGF-binding molecules on the duration of VEGF suppression.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
2秒前
你比我笨发布了新的文献求助10
4秒前
4秒前
SOLOMON举报90无脸男求助涉嫌违规
6秒前
CodeCraft应助wm采纳,获得10
6秒前
7秒前
7秒前
8秒前
8秒前
栗子发布了新的文献求助80
12秒前
S.leeper完成签到,获得积分10
13秒前
aaaaaa完成签到,获得积分20
14秒前
肖旻发布了新的文献求助30
15秒前
普通市民7v7完成签到,获得积分20
15秒前
18秒前
21秒前
aaaaaa发布了新的文献求助20
21秒前
23秒前
派对动物完成签到 ,获得积分10
24秒前
24秒前
万能图书馆应助悦子采纳,获得10
24秒前
26秒前
hzc发布了新的文献求助10
27秒前
guo完成签到,获得积分20
27秒前
Singularity应助易殇采纳,获得10
27秒前
畅快枕头发布了新的文献求助10
30秒前
guo发布了新的文献求助10
30秒前
32秒前
研友完成签到,获得积分10
32秒前
懵懂的小夏完成签到,获得积分10
33秒前
34秒前
GSQ发布了新的文献求助10
34秒前
甜蜜土豆完成签到,获得积分10
35秒前
爆米花应助农大彭于晏采纳,获得10
36秒前
37秒前
37秒前
bkagyin应助夏日染成空白采纳,获得50
38秒前
39秒前
不安的白秋完成签到,获得积分20
39秒前
39秒前
高分求助中
One Man Talking: Selected Essays of Shao Xunmei, 1929–1939 1000
Yuwu Song, Biographical Dictionary of the People's Republic of China 700
[Lambert-Eaton syndrome without calcium channel autoantibodies] 520
Sphäroguß als Werkstoff für Behälter zur Beförderung, Zwischen- und Endlagerung radioaktiver Stoffe - Untersuchung zu alternativen Eignungsnachweisen: Zusammenfassender Abschlußbericht 500
少脉山油柑叶的化学成分研究 430
Sport 400
Revolutions 400
热门求助领域 (近24小时)
化学 材料科学 医学 生物 有机化学 工程类 生物化学 纳米技术 物理 内科学 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 电极 光电子学 量子力学
热门帖子
关注 科研通微信公众号,转发送积分 2454120
求助须知:如何正确求助?哪些是违规求助? 2126033
关于积分的说明 5414461
捐赠科研通 1854720
什么是DOI,文献DOI怎么找? 922437
版权声明 562326
科研通“疑难数据库(出版商)”最低求助积分说明 493552